Vitamin D deficiency in pediatric clinical practice

Cediel, Gustavo; Pacheco-Acosta, Johanna; CastiUo-Durdn, Carlos

doi:10.5546/aap.2018.eng.e75

Cited by 30 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional potential adverse outcomes of furosemide use in premature infants include metabolic bone disease (osteopenia) of prematurity and electrolyte abnormalities related to urinary loss of sodium, chloride, and calcium [ 53 – 55 ]. As with other adverse outcomes, the etiology of metabolic bone disease in premature infants likely has many causes, and infants with severe illness often have multiple risk factors such as insufficient phosphorus intake, vitamin D deficiency, prolonged immobilization, mechanical ventilation, and exposure to steroids and antibiotics [ 56 – 58 ]. However, there is a lack of consensus on the definition of metabolic bone disease of prematurity, with some definitions relying on serum mineral levels and others based on radiographical findings [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Jackson

Taylor

Selewski

et al. 2018

matern health, neonatol and perinatol

View full text Add to dashboard Cite

Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and lung compliance in premature infants. There are several safety concerns with use of furosemide in premature infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We conducted a systematic review of all trials and observational studies examining the association between these outcomes with exposure to furosemide in premature infants.We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov. We included studies reporting either SNHL or NC/NL in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining SNHL and 20 studies examining NC/NL. Only one randomized controlled trial was identified in this review. We found no evidence that furosemide exposure increases the risk of SNHL or NC/NL in premature infants, with varying quality of studies and found the strength of evidence for both outcomes to be low. The most common limitation in these studies was the lack of control for confounding factors.The evidence for the risk of SNHL and NC/NL in premature infants exposed to furosemide is low. Further randomized controlled trials of furosemide in premature infants are urgently needed to adequately assess the risk of SNHL and NC/NL, provide evidence for improved FDA labeling, and promote safer prescribing practices.Electronic supplementary materialThe online version of this article (10.1186/s40748-018-0092-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Jackson

Taylor

Selewski

et al. 2018

matern health, neonatol and perinatol

View full text Add to dashboard Cite

show abstract

“…Vitamin D is a key factor in the regulation of bone mineralization and calcium homeostasis in both genders. Vitamin D deficiency is widespread worldwide [ 23 ]. A recent study has confirmed that vitamin D receptors are widely present in ovary, testis, pituitary, hypothalamus, and the reproductive system is one of the target organs of vitamin D, indicating that vitamin D may be involved in the regulation of gonadal function [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism

et al. 2021

View full text Add to dashboard Cite

Background The purpose of this study was to investigate the application value of serum 25(OH)D3, uric acid, triglyceride (TG), and homeostasis model assessment of insulin resistance (HOMA-IR) in male patients with hyperuricemia combined with hypogonadism. Methods From August 2018 to August 2020, a total of 198 male patients with primary hyperuricemia were prospectively enrolled in our hospital for inpatient treatment in the department of Metabolism and Endocrinology. They are divided into normal gonadal function group (normal group, n = 117) and hypogonadal function group (hypogonadism group, n = 81), according to free testosterone (FT) level, International Index of Erectile Function (IIEF-5), and androgen deficiency in the aging male (ADAM) questionnaires. Laboratory indexes were compared between two groups. Multivariate logistic regression was applied to analyze the influencing factors of hypogonadism. Results Among the 198 hyperuricemia patients, 40.91 % were hypogonadism. Compared with the normal group, the BMI, waist circumference (WC), and the prevalence of non-alcoholic fatty liver disease (NAFLD), hyperlipidemia (HLP), and obesity (OB) in the hypogonadism group were higher, and the difference was statistically significant (P < 0.05, respectively). The levels of fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), triacylglycerol (TG), serum uric acid (SUA), alanine transaminase (ALT) of hypogonadism group were higher than those of normal group, while the levels of TT, FT, E2, 25(OH)D3 of hypogonadism group were lower than those of normal group (P < 0.05, respectively). Pearson’s linear correlation was used to analyze the correlation between the indicators with significant differences in general data and laboratory indicators and hypogonadism. BMI, WC, HOMA-IR, TG, SUA, TT, FT, 25(OH)D3, E2 were positively correlated with hypogonadism (r = 0.556, 0.139, 0.473, 0.143, 0.134, 0.462, 0.419, 0.572, 0.601, P = 0.012, 0.027, 0.018, 0.019, 0.028, 0.029, 0.030, 0.009, 0.003, respectively). Taking the above indicators as independent variables and hypogonadism as the dependent variable, logistic regression analysis found that the risk factors for hypogonadism were SUA, WC, BMI, HOMA-IR, TG, TT, FT, E2, and 25(OH) D3. Conclusions Serum 25(OH)D3, SUA, HOMA-IR, TG levels were positively correlated with male hyperuricemia patients with hypogonadism. They have important application value in the diagnosis of male hyperuricemia patients with hypogonadism.

show abstract

“…Interest in vitamin D and its properties has increased significantly over the past two decades. Numerous studies conducted in various regions of the world indicate that vitamin D deficiencies occur in all countries, regardless of the latitude and age [15][16][17][18]. This is also true for Polish children.…”

Section: Discussionmentioning

confidence: 99%

Effect of Vitamin D Treatment on Dynamics of Stones Formation in the Urinary Tract and Bone Density in Children with Idiopathic Hypercalciuria

et al. 2020

View full text Add to dashboard Cite

Vitamin D supplementation in patients with urolithiasis and hypercalciuria is considered to be unsafe. We analyzed the impact of vitamin D supplementation on selected health status parameters in children with idiopathic hypercalciuria. The study included 36 children with urolithiasis resulting from excessive calcium excretion. The level of calcium and 25(OH)D (hydroxylated vitamin D - calcidiol) in serum, urinary calcium excretion and the presence of stones in urinary tract were assessed prospectively. Blood and urine samples were collected at the time when the patient was qualified for the study and every three months up to 24 month of vitamin D intake at a dose of 400 or 800 IU/day. At time zero and at 12, and 24 months of vitamin D supplementation, densitometry was performed. Supplementation with vitamin D caused a statistically significant increase in the concentration of 25(OH)D in serum. There were no significant changes in calcium concentration in serum, excretion of calcium in urine but also in bone density. There was no significant increase in the risk of formation or development of stones in the urinary tract. Supplementation with vitamin D (400–800 IU/day) in children with idiopathic hypercalciuria significantly increases 25(OH)D concentration, does not affect calciuria, but also does not improve bone density.

show abstract

Vitamin D deficiency in pediatric clinical practice

Cited by 30 publications

References 44 publications

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism

Effect of Vitamin D Treatment on Dynamics of Stones Formation in the Urinary Tract and Bone Density in Children with Idiopathic Hypercalciuria

Contact Info

Product

Resources

About